Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
25.78 USD -0.15% Intraday chart for Genmab A/S -0.08% -19.03%
06-10 Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
06-04 Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S : has published its Articles of Association
PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
Genmab A/S - Transactions in Connection with Share Buy-back Program
AQ
Transactions in Connection with Share Buy-back Program
GL
Transactions in Connection with Share Buy-back Program
AQ
Genmab A/S : has published its Articles of Association
PU
Genmab A/S - Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
Grant of Restricted Stock Units and Warrants to Employees in Genmab
GL
Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GL
Transactions in Connection with Share Buy-back Program
GL
Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
GL
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating
MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study
MT
Transcript : Genmab A/S - Special Call
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
BU
Transactions in Connection with Share Buy-back Program
GL
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GMAB Stock
  5. News Genmab A/S